2021 Revenues ($USD) : $5,821,079,240
2021 Revenues (foreign currencies) : €4,933,118,000
2021 R&D spend : $388,220,000
2021 Number of Employees : 23,000
Fiscal Year End : 12/31/2021
Leader : Co-CEOs Víctor Grifols Deu and Raimon Grifols

Founded in 1909, the Spanish multinational pharmaceutical company is best known as a maker of blood-plasma-based products such as immunoglobin therapy and albumin. The company is divided into bioscience, diagnostic, hospital and biosupplies divisions. It offers products and services in more than 100 countries and has subsidiaries in more than 30 countries and regions. The company joined the Madrid Stock Exchange in 2006, which became part of the IBEX 35 index in 2008. In March 2022, Grifols acquired Germany-based Tiancheng Pharmaceutical Holdings, majority owner of hematology and immunology specialist Biotest AG. Grifols has a biotech subsidiary known as GigaGen Inc., which focuses on antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers. —BB